The FDA has approved Bystolic (nebivolol, from Forest Laboratories and Mylan), a once-daily beta blocker for use as monotherapy or in combination with other antihypertensive agents. In clinical trials, Bystolic demonstrated significant reductions in sitting diastolic and systolic blood pressure in a general hypertensive population. Bystolic is expected to be available in January 2008.

For more information call (800) 678-1605 or visit www.Bystolic.com.